Bänsch D, Castrucci M, Böcker D, Breithardt G, Block M
Department of Cardiology/Angiology and Institute for Research in Arteriosclerosis, Westfälische Wilhelms-University, Münster, Germany.
J Am Coll Cardiol. 2000 Aug;36(2):557-65. doi: 10.1016/s0735-1097(00)00733-6.
This retrospective study was performed to provide data on ventricular tachycardias (VT) with a cycle length longer than the initially programmed tachycardia detection interval (TDI) in patients with implantable cardioverter defibrillators (ICDs).
It has been clinical practice to program a safety margin of 30 to 60 ms between the slowest spontaneous or inducible VT and the TDI.
Baseline characteristics of 659 consecutive patients with ICDs were prospectively; follow-up information was retrospectively collected.
During a mean follow-up of 31+/-23 months, 377 patients (57.2%) had at least one recurrent VT or ventricular fibrillation; 47 patients (7.1%) suffered 61 VTs above the TDI. The risk of a VT above the TDI ranged between 2.7% and 3.5% per year during the first four years after ICD implantation. The difference between the cycle length of the slowest VT before ICD implantation, spontaneous or induced, and the first VT above TDI was 108+/-58 ms. Fifty-four VTs (88.5%) above the TDI were associated with significant clinical symptoms (angina or palpitation 63.9%, heart failure 6.6% and syncope 8.2%). Six patients (9.8%) had to be resuscitated. Kaplan-Meyer analysis identified New York Heart Association class II or III (p = 0.021), ejection fraction < 0.40 (p = 0.027), spontaneous (p<0.001) or inducible (p<0.001) monomorphic VTs and the use of class III antiarrhythmic drugs (amiodarone, p<0.001; sotalol, p = 0.004) as risk predictors of VTs above the TDI. The risk of recurrent VTs above TDI was 11.8%, 12.5% and 26.6% during the first, second and third year after first VT above TDI, respectively.
The risk of VTs above the TDI is significantly increased in some patients, and many VTs above TDI cause significant clinical symptoms. A larger safety margin between spontaneous or inducible VTs and the TDI seems to be necessary in selected patients. This is in conflict with an increased risk of inadequate episodes and demands highly specific and sensitive detection algorithms in these patients.
本回顾性研究旨在提供有关植入式心脏复律除颤器(ICD)患者中,室性心动过速(VT)周期长度长于最初程控的心动过速检测间期(TDI)的数据。
在最慢的自发或诱发室性心动过速与心动过速检测间期之间设置30至60毫秒的安全裕度一直是临床实践。
前瞻性收集659例连续ICD患者的基线特征;回顾性收集随访信息。
在平均31±23个月的随访期间,377例患者(57.2%)至少发生一次复发性室性心动过速或心室颤动;47例患者(7.1%)发生61次周期长度超过心动过速检测间期的室性心动过速。在植入ICD后的前四年中,周期长度超过心动过速检测间期的室性心动过速的年发生率在2.7%至3.5%之间。植入ICD前自发或诱发的最慢室性心动过速的周期长度与首次周期长度超过心动过速检测间期的室性心动过速之间的差值为108±58毫秒。61次周期长度超过心动过速检测间期的室性心动过速中有54次(88.5%)伴有明显的临床症状(心绞痛或心悸63.9%,心力衰竭6.6%,晕厥8.2%)。6例患者(9.8%)需要进行心肺复苏。Kaplan-Meier分析确定纽约心脏协会II或III级(p = 0.021)、射血分数<0.40(p = 0.027)、自发(p<0.001)或诱发(p<0.001)的单形性室性心动过速以及使用III类抗心律失常药物(胺碘酮,p<0.001;索他洛尔,p = 0.004)是周期长度超过心动过速检测间期的室性心动过速的风险预测因素。在首次发生周期长度超过心动过速检测间期的室性心动过速后的第一、第二和第三年,周期长度超过心动过速检测间期的复发性室性心动过速的风险分别为11.8%、12.5%和26.6%。
部分患者中周期长度超过心动过速检测间期的室性心动过速的风险显著增加,且许多周期长度超过心动过速检测间期的室性心动过速会引起明显的临床症状。对于部分患者,在自发或诱发的室性心动过速与心动过速检测间期之间似乎需要更大的安全裕度。这与不适当发作风险增加相矛盾,并且在这些患者中需要高度特异性和敏感性的检测算法。